ArticleBJS open2020
Tumour growth rate of carcinoma of the colon and rectum: retrospective cohort study.
Article in BJS open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The effect of time before diagnosis and treatment on colorectal cancer outcomes: systematic review and dose-response meta-analysis.British journal of cancer · 2023Pooled it
- The Association Between Treatment Interval and Survival in Patients With Colon or Rectal Cancer: A Systematic Review.World journal of surgery · 2021Pooled it
- Estimating the carcinogenesis timelines in early-onset versus late-onset cancers and changes across birth cohorts.Science advances · 2026Article
- tugMedi: simulator of cancer-cell evolution for personalized medicine based on the genomic data of patients.NPJ systems biology and applications · 2026Article
- Modeling Early-Onset Cancer Kinetics Reveals Changes in Underlying Risk and the Impact of Population Screening.Cancer research · 2025Article
- The pathway to diagnosis of early-onset colorectal cancer: exploring diagnostic intervals and their effect on outcomes.Future oncology (London, England) · 2025Article
- The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.Biomolecules · 2025Review
- Modeling early-onset cancer kinetics to study changes in underlying risk, detection, and impact of population screening.medRxiv : the preprint server for health sciences · 2025Article
- Titin gene mutations enhance radiotherapy efficacy via modulation of tumour immune microenvironment in rectum adenocarcinoma.Clinical and translational medicine · 2025Article
- Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach.The AAPS journal · 2024Article
- Understanding patient-derived tumor organoid growth through an integrated imaging and mathematical modeling framework.PLoS computational biology · 2024Article
- Early rectal cancer: The diagnostic performance of MRI supplemented with a rectal micro-enema and a modified staging system to identify tumors eligible for local excision.Acta radiologica open · 2024Article
- Management of obstructed colorectal carcinoma in an emergency setting: An update.World journal of gastrointestinal oncology · 2024Review
- Minimum latency effects for cancer associated with exposures to radiation or other carcinogens.British journal of cancer · 2024Article
- Article
- Delays in Colorectal Cancer Screening for Latino Patients: The Role of Immigrant Healthcare in Stemming the Rising Global Incidence of Colorectal Cancer.Gastroenterology research · 2024Article
- LI-RADS threshold growth based on tumor growth rate can improve the diagnosis of hepatocellular carcinoma ≤ 3.0 cm.European radiology · 2024Article
- Model-based prediction of progression-free survival for combination therapies in oncology.CPT: pharmacometrics & systems pharmacology · 2023Article
- Endoscopy Lifetime Systems Architecture: Scoping Out the Past to Diagnose the Future Technology.Systems · 2022Article
- Evaluating potential delays and outcomes of patients undergoing surgical resection for locally advanced and recurrent colorectal cancer during a pandemic.Annals of the Royal College of Surgeons of England · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe growth pattern of colorectal cancer is seldom investigated. This cohort study aimed to explore tumour growth rate in colorectal cancers managed non-surgically or deemed not resectable, and to determine its implication for prognosis.
methodsConsecutive patients with colonic or rectal adenocarcinoma were identified through the colorectal multidisciplinary team database at Leeds Teaching Hospitals NHS Trust over a 2-year interval. Patients who received no treatment (surgery, stenting, colonic defunctioning procedures, chemotherapy, radiotherapy) and who underwent CT twice more than 5 weeks apart were included. Multidetector CT/three-dimensional image analysis was performed independently by three experienced radiologists.
resultsOf 804 patients reviewed, 43 colorectal cancers were included in the final analysis. Median age at first CT was 80 (73-85) years and the median interval between scans was 150 (i.q.r. 72-471) days. An increase in T category was demonstrated in 31 of 43 tumours, with a median doubling time of 211 (112-404) days. The median percentage increase in tumour volume was 34·1 (13·3-53·9) per cent per 62 days. The all-cause 3-year mortality rate was 81 per cent (35 of 43) with a median survival time of 1·1 (0·4-2·2) years after the initial diagnostic scan. In those obstructed, the relative risk of death from subsequent perforation was 1·26 (95 per cent c.i. 1·07 to 1·49; P = 0·005).
conclusionThis study documented a median doubling time of 211 days, with a concerning suggestion of tumour progression, which has implications for the current management standard.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.